Fig. 3
A comparison of vaccination approaches for augmenting T-cell engraftment. Vaccination approaches for augmenting lymphocyte engraftment were evaluated by infusing 1 × 107 CD8+ T cells genome-modified with the pT-effluc-thy1.1 transposon. a Schematic representation of experiments comparing (i) subdermal vaccination (s.d.) and (ii) intravenous (i.v.) vaccination; yellow cells indicate T cells transfected with pT-effluc-thy1.1 and pCMV-m7pB, blue cells indicate vaccine T cells transfected with pTSB-CAG-OVA and pCMV-SB100X. b Representative bioluminescent images taken 21 days after iv transfer of 1 × 107 genome-modified CD8+ T cells comparing the engraftment facilitated by a subdermal plasmid vaccine regimen (left panels) or an i.v. OT-1 T-cell vaccine (D, dorsal; V, ventral) (N = 5). c Plot showing total (dorsal + ventral) luciferase signals measured in mice that received either two subdermal plasmid vaccines at days 1 and 10 after transfer (red arrows), or a single i.v. OT-1 T-cell vaccine concomitantly during autologous transfer. Dashed line indicates mean luminescence signal observed in mice injected with saline without d-luciferin (N = 5 ± SEM, *p < 0.05 using Student’s T-test comparing at given time points). d Plot showing area under the curve for the sum total of the measurements presented in c (N = 5 ± SEM, *p < 0.05 using Student’s T-test)
